Seres Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Seres Therapeutics, Inc. (MCRB) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $43.02 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2022-03-01
- Seres Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2019-03-31 was -$1.65M.
- Seres Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2018-12-31 was -$529.00K, a 116.39% decline year-over-year.
- Seres Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2018-09-30 was $549.00K.
- Seres Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2018-06-30 was $1.50M, a 168.82% increase year-over-year.
- Seres Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2021 was $43.02M, a 1040.94% increase from fiscal 2020.
- Seres Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2020 was $3.77M.
- Seres Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2019 was -$2.91M, a 497.27% decline from fiscal 2018.
- Seres Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2018 was $732.00K, a 66.14% decline from fiscal 2017.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2021-12-31 | $43.02M 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $3.77M 10-K · filed 2022-03-01 | |||
| 2019-12-31 | -$2.91M 10-K · filed 2022-03-01 | |||
| 2019-03-31 | -$1.65M 10-Q · filed 2019-05-02 | -$2.18M derived: sum of 2 quarters · filed 2021-03-02 | -$1.63M derived: sum of 3 quarters · filed 2021-03-02 | -$130.00K derived: sum of 4 quarters · filed 2021-03-02 |
| 2018-12-31 | -$529.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $20.00K derived: sum of 2 quarters · filed 2021-03-02 | $1.52M derived: sum of 3 quarters · filed 2021-03-02 | $732.00K 10-K · filed 2021-03-02 |
| 2018-09-30 | $549.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $2.05M derived: sum of 2 quarters · filed 2018-11-08 | $1.26M 10-Q · filed 2018-11-08 | $4.49M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $712.00K 10-Q · filed 2018-08-02 | $3.94M derived: sum of 3 quarters · filed 2020-03-02 | $3.45M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$788.00K 10-Q · filed 2019-05-02 | $2.44M derived: sum of 2 quarters · filed 2020-03-02 | $1.95M derived: sum of 3 quarters · filed 2020-03-02 | $2.51M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $2.74M derived: sum of 2 quarters · filed 2020-03-02 | $3.30M derived: sum of 3 quarters · filed 2020-03-02 | $2.16M 10-K · filed 2020-03-02 |
| 2017-09-30 | -$488.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $70.00K derived: sum of 2 quarters · filed 2018-11-08 | -$1.06M 10-Q · filed 2018-11-08 | -$2.90M derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-06-30 | $558.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$577.00K 10-Q · filed 2018-08-02 | -$2.42M derived: sum of 3 quarters · filed 2019-03-06 | $2.46M derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-03-31 | -$1.14M 10-Q · filed 2018-05-09 | -$2.97M derived: sum of 2 quarters · filed 2019-03-06 | $1.90M derived: sum of 3 quarters · filed 2019-03-06 | $4.70M derived: sum of 4 quarters · filed 2019-03-06 |
| 2016-12-31 | -$1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $3.04M derived: sum of 2 quarters · filed 2019-03-06 | $5.83M derived: sum of 3 quarters · filed 2019-03-06 | $5.03M 10-K · filed 2019-03-06 |
| 2016-09-30 | $4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $7.67M derived: sum of 2 quarters · filed 2017-11-08 | $6.87M 10-Q · filed 2017-11-08 | $9.07M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $1.99M 10-Q · filed 2017-08-03 | $4.20M derived: sum of 3 quarters · filed 2018-03-08 | $4.78M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | -$806.00K 10-Q · filed 2017-05-04 | $1.40M derived: sum of 2 quarters · filed 2018-03-08 | $1.98M derived: sum of 3 quarters · filed 2018-03-08 | $2.83M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $2.79M derived: sum of 2 quarters · filed 2018-03-08 | $3.63M derived: sum of 3 quarters · filed 2018-03-08 | $2.93M 10-K · filed 2018-03-08 |
| 2015-09-30 | $583.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.43M derived: sum of 2 quarters · filed 2016-11-10 | $724.00K 10-Q · filed 2016-11-10 | $1.89M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $847.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $141.00K 10-Q · filed 2016-08-11 | $1.31M derived: sum of 3 quarters · filed 2017-03-16 | $1.38M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | -$706.00K 10-Q · filed 2016-05-16 | $463.00K derived: sum of 2 quarters · filed 2017-03-16 | $529.00K derived: sum of 3 quarters · filed 2017-03-16 | |
| 2014-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $1.24M derived: sum of 2 quarters · filed 2017-03-16 | $1.47M 10-K · filed 2017-03-16 | |
| 2014-09-30 | $66.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $305.00K 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $239.00K 10-Q · filed 2015-08-10 | |||
| 2013-12-31 | $197.00K 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |